Sellas Life Sciences Group Inc (SLS)

NASDAQ
Currency in USD
1.400
+0.060(+4.48%)
Closed·
After Hours
1.420+0.040(+2.899%)
·
SLS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 10 days
Fair Value
Day's Range
1.3601.470
52 wk Range
0.7721.840
Key Statistics
Edit
Prev. Close
1.34
Open
1.36
Day's Range
1.36-1.47
52 wk Range
0.772-1.84
Volume
2.44M
Average Vol. (3m)
1.97M
1-Year Change
-4.11%
Book Value / Share
0.13
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SLS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.833
Upside
+316.67%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory
Show more

Sellas Life Sciences Group Inc Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Compare SLS to Peers and Sector

Metrics to compare
SLS
Peers
Sector
Relationship
P/E Ratio
−4.1x−0.3x−0.5x
PEG Ratio
−0.070.010.00
Price / Book
13.4x2.0x2.6x
Price / LTM Sales
-11.2x2.9x
Upside (Analyst Target)
328.6%198.8%57.1%
Fair Value Upside
Unlock11.4%9.0%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 5.833
(+316.67% Upside)

Earnings

Latest Release
Mar 20, 2025
EPS / Forecast
-0.06 / -0.10
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

7.920
MLGO
-8.86%
3.390
PL
+1.19%
1.1700
TNON
+1.74%
2.6850
SUNE
-9.90%
12.330
HOLO
-15.84%

FAQ

What Is the Sellas Life Sciences (SLS) Stock Price Today?

The Sellas Life Sciences stock price today is 1.40

What Stock Exchange Does Sellas Life Sciences Trade On?

Sellas Life Sciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Sellas Life Sciences?

The stock symbol for Sellas Life Sciences is "SLS."

What Is the Sellas Life Sciences Market Cap?

As of today, Sellas Life Sciences market cap is 127.19M.

What is Sellas Life Sciences Earnings Per Share?

The Sellas Life Sciences EPS is -0.50.

What Is the Next Sellas Life Sciences Earnings Date?

Sellas Life Sciences will release its next earnings report on May 08, 2025.

From a Technical Analysis Perspective, Is SLS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.